Key Points
- Insider selling: EVP Allison Swartz sold 599 shares on March 4 at $17.54 for $10,506.46 and also sold 4,657 and 2,199 shares on March 3 and March 2, respectively, trimming her stake by 0.67% to 88,941 shares (≈$1.56M).
- Company performance and outlook: Progyny beat Q results with $0.48 EPS vs. $0.38 expected and $318.4M revenue, set FY2026 guidance of $1.83–$1.95 EPS (Q1 0.42–0.45), and trades near $18.31 amid a "Moderate Buy" analyst consensus and an average target of about $29.
Progyny, Inc. (NASDAQ:PGNY - Get Free Report) EVP Allison Swartz sold 599 shares of the firm's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $17.54, for a total value of $10,506.46. Following the transaction, the executive vice president owned 88,941 shares in the company, valued at approximately $1,560,025.14. This trade represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Allison Swartz also recently made the following trade(s):
- On Tuesday, March 3rd, Allison Swartz sold 4,657 shares of Progyny stock. The stock was sold at an average price of $17.40, for a total value of $81,031.80.
- On Monday, March 2nd, Allison Swartz sold 2,199 shares of Progyny stock. The stock was sold at an average price of $17.27, for a total value of $37,976.73.
Progyny Stock Performance
Shares of NASDAQ PGNY traded up $0.69 during mid-day trading on Friday, reaching $18.31. 1,805,320 shares of the company traded hands, compared to its average volume of 1,690,778. The company's fifty day moving average is $23.09 and its two-hundred day moving average is $22.92. Progyny, Inc. has a fifty-two week low of $16.75 and a fifty-two week high of $28.75. The stock has a market cap of $1.50 billion, a PE ratio of 28.17, a price-to-earnings-growth ratio of 1.20 and a beta of 1.01.
Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. The firm had revenue of $318.40 million during the quarter, compared to analyst estimates of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company's revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Research analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.
Institutional Trading of Progyny
Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company's stock worth $217,484,000 after purchasing an additional 235,513 shares during the last quarter. State Street Corp raised its position in shares of Progyny by 1.5% during the fourth quarter. State Street Corp now owns 2,953,186 shares of the company's stock valued at $75,838,000 after buying an additional 44,642 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company's stock valued at $57,607,000 after buying an additional 1,621,688 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company's stock valued at $43,933,000 after buying an additional 545,431 shares during the period. Finally, Geode Capital Management LLC grew its position in Progyny by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company's stock worth $50,655,000 after buying an additional 20,533 shares in the last quarter. 94.93% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several analysts recently issued reports on the stock. Wall Street Zen raised shares of Progyny from a "hold" rating to a "buy" rating in a report on Saturday, January 3rd. Barclays began coverage on shares of Progyny in a report on Monday, December 8th. They set an "overweight" rating and a $29.00 price target for the company. Jefferies Financial Group reiterated a "buy" rating and issued a $30.00 price objective on shares of Progyny in a research note on Friday. Canaccord Genuity Group boosted their price objective on Progyny from $23.00 to $26.00 and gave the stock a "hold" rating in a research report on Monday, November 17th. Finally, Citizens Jmp upgraded Progyny from a "market perform" rating to an "outperform" rating and set a $30.00 target price for the company in a research note on Tuesday, January 20th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $29.09.
Check Out Our Latest Analysis on Progyny
About Progyny
(
Get Free Report)
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
